Stryker (NYSE:SYK) Stock Rating Lowered by Wall Street Zen

Key Points

• Stryker's stock rating was lowered from "buy" to "hold" by Wall Street Zen, reflecting a changing sentiment among analysts.
• The current consensus ratings on Stryker's stock indicate a "Moderate Buy" with an average target price of $430.33.
• In recent insider transactions, Director Ronda E. Stryker sold 200,000 shares, leading to a 5.84% decrease in her stock position.

Stryker (NYSE:SYK - Get Free Report) was downgraded by equities researchers at Wall Street Zen from a "buy" rating to a "hold" rating in a note issued to investors on Friday.

Other equities research analysts also recently issued research reports about the company. Rothschild Redb upgraded Stryker to a "hold" rating in a research report on Thursday, September 18th. Needham & Company LLC boosted their price objective on Stryker from $442.00 to $448.00 and gave the stock a "buy" rating in a report on Friday, August 1st. Evercore ISI upped their target price on shares of Stryker from $390.00 to $415.00 and gave the company an "outperform" rating in a research report on Tuesday, July 8th. Rothschild & Co Redburn started coverage on shares of Stryker in a research report on Thursday, September 18th. They set a "neutral" rating and a $420.00 price target for the company. Finally, BTIG Research restated a "buy" rating on shares of Stryker in a report on Monday, July 14th. Fourteen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, Stryker presently has an average rating of "Moderate Buy" and a consensus target price of $430.33.

Stryker Stock Performance

Stryker stock opened at $368.83 on Friday. The stock has a 50-day simple moving average of $385.71 and a 200 day simple moving average of $378.97. The stock has a market capitalization of $141.01 billion, a price-to-earnings ratio of 48.85, a P/E/G ratio of 2.66 and a beta of 0.93. The company has a quick ratio of 1.06, a current ratio of 1.78 and a debt-to-equity ratio of 0.70. Stryker has a 12-month low of $329.16 and a 12-month high of $406.19.

Stryker (NYSE:SYK - Get Free Report) last posted its quarterly earnings data on Thursday, July 31st. The medical technology company reported $3.13 earnings per share for the quarter, beating the consensus estimate of $3.07 by $0.06. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The firm had revenue of $6.02 billion during the quarter, compared to analysts' expectations of $5.92 billion. During the same quarter last year, the company posted $2.81 EPS. The company's quarterly revenue was up 11.1% compared to the same quarter last year. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. On average, research analysts anticipate that Stryker will post 13.47 earnings per share for the current fiscal year.

Insider Buying and Selling at Stryker

In related news, Director Ronda E. Stryker sold 200,000 shares of the company's stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $376.45, for a total value of $75,290,000.00. Following the completion of the sale, the director owned 3,222,108 shares in the company, valued at $1,212,962,556.60. This represents a 5.84% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Viju Menon sold 500 shares of Stryker stock in a transaction dated Monday, August 25th. The stock was sold at an average price of $390.61, for a total value of $195,305.00. Following the transaction, the insider owned 12,511 shares in the company, valued at approximately $4,886,921.71. This represents a 3.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.90% of the stock is owned by insiders.

Institutional Trading of Stryker

A number of large investors have recently bought and sold shares of SYK. Mid American Wealth Advisory Group Inc. bought a new stake in shares of Stryker during the second quarter worth $26,000. Elevation Point Wealth Partners LLC acquired a new position in Stryker in the 2nd quarter worth $28,000. Sachetta LLC increased its holdings in Stryker by 58.7% during the 2nd quarter. Sachetta LLC now owns 73 shares of the medical technology company's stock worth $29,000 after purchasing an additional 27 shares in the last quarter. Kilter Group LLC acquired a new stake in shares of Stryker in the 2nd quarter valued at about $29,000. Finally, Howard Hughes Medical Institute bought a new stake in shares of Stryker in the second quarter valued at about $29,000. 77.09% of the stock is owned by institutional investors.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.